Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia Marco Meglio

Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.

This Week on NeurologyLive® — January 19, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: January 18, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient Noah Stansfield

The therapy also received orphan drug designation from the FDA.

NeurologyLive® Friday 5 — January 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Amantadine Immediate Release Lowers Dyskinesia Risk in Early Parkinson Disease, Study Shows Louie Pasculli

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

Todays Updates

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus Chelsie Derman

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

What the EC Decision on High-Dose Spinraza Means for SMA Care Marco Meglio, Stephanie Fradette, PhD

Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

Todays Updates

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus Chelsie Derman

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

What the EC Decision on High-Dose Spinraza Means for SMA Care Marco Meglio, Stephanie Fradette, PhD

Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

Latest News

Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!

The therapy also received orphan drug designation from the FDA.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

News All Time

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Neuroprotective Agent Privosegtor Gains FDA Breakthrough Designation for Optic Neuritis Marco Meglio

Oculis advances Privosegtor, a potential first neuroprotective therapy for optic neuritis, following FDA breakthrough designation and promising trial results.

Annexon Submits Marketing Authorization Application for Tanruprubart to Treat Guillain-Barré Syndrome Louie Pasculli

Annexon submitted an EMA marketing application for tanruprubart, a first-in-class C1q monoclonal antibody that showed faster and more complete recovery in Guillain-Barré syndrome patients across randomized trials.

This Week on NeurologyLive® — January 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Published Phase 2 Data Highlight Potential of NNZ-2591 in Phelan-McDermid Syndrome Marco Meglio

A phase 2 trial shows NNZ-2591 improves symptoms in children with Phelan-McDermid syndrome, paving the way for a phase 3 study.

NeurologyLive® Friday 5 — January 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.

Oral Anticoagulants Do Not Raise ARIA Risk of Anti-Amyloid Alzheimer Therapies, Study Shows Louie Pasculli

A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.

NeurologyLive® Brain Games: January 11, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!

Inside the 2026 MDA Conference: Emerging Research Themes in Neuromuscular Medicine Marco Meglio, Angela Lek, PhD

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.

BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies Marco Meglio

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Episode 158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies Marco Meglio, Johannes Streffer, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

Key Neurology Trial Readouts to Watch in Early 2026 Isabella Ciccone, MPH

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

NeuroVoices: Christina Briscoe, MD; Emily Spelbrink, MD, PhD, on Addressing Equity Gaps in Infantile Epileptic Spasms Syndrome Marco Meglio, Christina Briscoe, MD, Emily Spelbrink, MD, PhD

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

AES Poster Shines Light on Positive Phase 3 GEMZ Study of Fenfluramine in CDKL5 Deficiency Disorder Marco Meglio

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Fenfluramine Treatment Leads to Long-Term Improved Everyday Executive Functioning in Lennox-Gastaut Syndrome Marco Meglio

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

Recommended News For You

Decrease seen in in situ breast cancer since 2009

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Cancer mortality continuing to decline, says report

Unlocking the secrets of the fibrotic fortress that surrounds and protects pancreatic cancer

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

Rising rates of head and neck cancers in England

When does a melanoma metastasize? Implications for management

Recommended Articles For You

The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer 

Understanding Axitinib: What You Need To Know For Your Treatment Plan 

Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment 

Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Medical Journal March 29, 2023

2.

Early breast cancer detection may be possible with a wearable ultrasound scanner.

3.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

4.

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

5.

Could CT scans be fueling a future rise in cancer cases, as a new study suggests?

1.

Exploring Dyscrasias: Uncovering the Causes and Treatments of Unusual Blood Disorders

2.

Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era

3.

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma 

4.

Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy

5.

All About Ferric Gluconate – The Best Source Of Iron For Anemia

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Oropharyngeal Cancer in Relation to HPV Status

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

3.

Navigating the Complexities of Ph Negative ALL - Part VIII

4.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

5.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot